TNFRSF4 and cancer: Specifically, numerous aptamers that target cancer-specific signature markers such as immunoinhibitory programmed death-1 [68], immune stimulating CD137 [69], CD134 [70], tumorigenic platelet-derived growth factor [71], and vascular endothelial growth factor [72] have been established.